RAPID-WATER-FLOW Trial
Phase 3
215
about 4.7 years
18+
7 sites in IA, MI, MN +4
About this study
Researchers are testing a new imaging test called O-15-Water PET myocardial perfusion imaging to help identify coronary artery disease. The trial will involve approximately 215 adults with suspected heart disease at multiple sites in the US and Europe. Participants will receive two doses of O-15-Water during a single PET scan, followed by a safety phone call.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Adverse event analyses will include tabulations of the incidence (number and percent of subjects) with at least one TEAEs overall and by MedDRA system organ class (SOC) and preferred term (PT). This will be repeated for serious adverse., Sensitivity, specificity, and accuracy of [15-O]-H2O PET MPI in participants of special clinical interest (female, BMI≥30, diabetics, multivessel disease).
Cardiology / Heart